Childhood obesity
endocrine · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
BMI at or above the 95th centile (or 98th centile on UK charts) for age and sex. The overwhelming majority is lifestyle-related; assessment screens for rare endocrine/syndromic causes and for comorbidities.
Red flags
- Obesity with short stature or slowing height velocity (endocrine cause)
- Developmental delay or dysmorphic features (syndromic cause)
- Rapid weight gain with signs of Cushing or hypothalamic lesion
- Symptoms of OSA, SUFE (hip/knee pain), or severe hypertension
Assessment
Differential diagnosis
- Exogenous (lifestyle) obesity (vast majority)
- Hypothyroidism
- Cushing syndrome / exogenous steroids
- Monogenic obesity (e.g. MC4R, leptin pathway)
- Syndromic obesity (Prader-Willi, Bardet-Biedl)
- Growth hormone deficiency
- Hypothalamic obesity (post tumour/surgery)
Investigations
- BMI centile and trend plotted on age/sex charts, waist circumference
- Blood pressure using appropriate cuff
- Fasting glucose/HbA1c and lipid profile in those at risk
- LFTs for non-alcoholic fatty liver disease
- TFTs and other endocrine tests only if short/slowing growth or clinical pointers
- Genetic testing if early severe obesity, developmental delay or dysmorphism
Management
- Confirm obesity using BMI centile and assess growth velocity
- Red-flag pathological causes: short stature, slowing growth, dysmorphism, developmental delay
- Take diet, activity, screen-time, sleep and family history
- Screen for comorbidities (hypertension, dyslipidaemia, dysglycaemia, NAFLD, OSA, orthopaedic)
- Assess psychosocial factors, mood and signs of disordered eating
- Deliver family-based lifestyle intervention (diet, activity, behaviour, screen-time)
- Treat identified comorbidities and refer for OSA/orthopaedic concerns
- Consider specialist tier for severe/complex obesity (pharmacotherapy/bariatric assessment in adolescents)
- Arrange regular supportive follow-up avoiding stigmatising language
Drugs & doses
No first-line drug; lifestyle change is the foundation of treatment
GLP-1 receptor agonists (e.g. liraglutide/semaglutide) in specialist adolescent services for selected cases
Orlistat occasionally used in adolescents under specialist supervision
Treat comorbidities (e.g. metformin for impaired glucose tolerance) per specialist
Disposition
Primary care/community lifestyle programmes; refer to specialist weight-management/endocrine service for red flags, severe obesity, or comorbidities.
Complications & pitfalls
- Type 2 diabetes and dyslipidaemia
- Non-alcoholic fatty liver disease and hypertension
- Obstructive sleep apnoea and slipped upper femoral epiphysis
- Psychological harm, bullying and low self-esteem
Exam pearls
- Obesity with declining height velocity suggests an endocrine cause and warrants investigation
- Most endocrine causes are associated with short, not tall, stature
- Family-based lifestyle change is more effective than targeting the child alone
- Use sensitive, non-stigmatising language with the child and family
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.